Extended Clinical Spectrum of Anti–N-Methyl-D-Aspartate Receptor Encephalitis in Children: A Case Series

Ajay Goenka, Vivek Jain, Hiroki Nariai, Alfred Spiro, Mitchell Steinschneider

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective There is a wide spectrum of clinical manifestations in children with anti–N-methyl-D-aspartate (NMDA) receptor antibody encephalitis from two different health care settings. Methods We describe our experience with 13 patients (median age, 7 years; range, 5 months to 19 years) presenting to tertiary referral centers in India and the United States. Results Initial manifestations were neurological (seizures or movement disorders) in eight patients, and psychiatric (e.g., emotional lability and hallucination) in five patients. Symptoms during the clinical course included seizures in ten patients, movement disorders (dyskinesia and choreiform movements) in 11 patients, and behavioral changes (aggressiveness and insomnia) in ten patients. Concomitant infections (herpes simplex virus 1, tuberculous meningitis, and influenza A) were present in three patients. Analysis of the cerebrospinal fluid in all except two cases preceded by infection (herpes simplex virus encephalitis and tuberculous meningitis) was unremarkable. Treatment included intravenous immunoglobulin/methylprednisolone (11 patients), rituximab (eight patients), plasmapheresis (two patients), and cyclophosphamide (two patients). Six patients recovered completely. Two patients had mild residual neurological deficits, whereas four had severe residual neurological deficits. Two patients had profound autonomic instability, which was the cause of death for one of them. Two patients relapsed at two and six months after the initial recovery. Conclusions We describe the differences and similarities of clinical presentation, test results, and response to treatment of children with anti–N-methyl-D-aspartate receptor encephalitis from India and the United States. Included is a description of one of the youngest patients with anti–N-methyl-D-aspartate receptor encephalitis (five months) and the first patient to be reported in association with tuberculous meningitis.

Original languageEnglish (US)
Pages (from-to)51-55
Number of pages5
JournalPediatric Neurology
Volume72
DOIs
StatePublished - Jul 1 2017

Fingerprint

D-Aspartic Acid
Encephalitis
Meningeal Tuberculosis
aspartic acid receptor
Movement Disorders
India
Herpes Simplex Encephalitis
Chorea
Plasmapheresis
Hallucinations
Intravenous Immunoglobulins

Keywords

  • acute psychosis
  • autonomic instability
  • movement disorder
  • seizures

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Neurology
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Extended Clinical Spectrum of Anti–N-Methyl-D-Aspartate Receptor Encephalitis in Children : A Case Series. / Goenka, Ajay; Jain, Vivek; Nariai, Hiroki; Spiro, Alfred; Steinschneider, Mitchell.

In: Pediatric Neurology, Vol. 72, 01.07.2017, p. 51-55.

Research output: Contribution to journalArticle

@article{5bd9190fca39406bb6ba7bf06b415f00,
title = "Extended Clinical Spectrum of Anti–N-Methyl-D-Aspartate Receptor Encephalitis in Children: A Case Series",
abstract = "Objective There is a wide spectrum of clinical manifestations in children with anti–N-methyl-D-aspartate (NMDA) receptor antibody encephalitis from two different health care settings. Methods We describe our experience with 13 patients (median age, 7 years; range, 5 months to 19 years) presenting to tertiary referral centers in India and the United States. Results Initial manifestations were neurological (seizures or movement disorders) in eight patients, and psychiatric (e.g., emotional lability and hallucination) in five patients. Symptoms during the clinical course included seizures in ten patients, movement disorders (dyskinesia and choreiform movements) in 11 patients, and behavioral changes (aggressiveness and insomnia) in ten patients. Concomitant infections (herpes simplex virus 1, tuberculous meningitis, and influenza A) were present in three patients. Analysis of the cerebrospinal fluid in all except two cases preceded by infection (herpes simplex virus encephalitis and tuberculous meningitis) was unremarkable. Treatment included intravenous immunoglobulin/methylprednisolone (11 patients), rituximab (eight patients), plasmapheresis (two patients), and cyclophosphamide (two patients). Six patients recovered completely. Two patients had mild residual neurological deficits, whereas four had severe residual neurological deficits. Two patients had profound autonomic instability, which was the cause of death for one of them. Two patients relapsed at two and six months after the initial recovery. Conclusions We describe the differences and similarities of clinical presentation, test results, and response to treatment of children with anti–N-methyl-D-aspartate receptor encephalitis from India and the United States. Included is a description of one of the youngest patients with anti–N-methyl-D-aspartate receptor encephalitis (five months) and the first patient to be reported in association with tuberculous meningitis.",
keywords = "acute psychosis, autonomic instability, movement disorder, seizures",
author = "Ajay Goenka and Vivek Jain and Hiroki Nariai and Alfred Spiro and Mitchell Steinschneider",
year = "2017",
month = "7",
day = "1",
doi = "10.1016/j.pediatrneurol.2017.03.010",
language = "English (US)",
volume = "72",
pages = "51--55",
journal = "Pediatric Neurology",
issn = "0887-8994",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Extended Clinical Spectrum of Anti–N-Methyl-D-Aspartate Receptor Encephalitis in Children

T2 - A Case Series

AU - Goenka, Ajay

AU - Jain, Vivek

AU - Nariai, Hiroki

AU - Spiro, Alfred

AU - Steinschneider, Mitchell

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Objective There is a wide spectrum of clinical manifestations in children with anti–N-methyl-D-aspartate (NMDA) receptor antibody encephalitis from two different health care settings. Methods We describe our experience with 13 patients (median age, 7 years; range, 5 months to 19 years) presenting to tertiary referral centers in India and the United States. Results Initial manifestations were neurological (seizures or movement disorders) in eight patients, and psychiatric (e.g., emotional lability and hallucination) in five patients. Symptoms during the clinical course included seizures in ten patients, movement disorders (dyskinesia and choreiform movements) in 11 patients, and behavioral changes (aggressiveness and insomnia) in ten patients. Concomitant infections (herpes simplex virus 1, tuberculous meningitis, and influenza A) were present in three patients. Analysis of the cerebrospinal fluid in all except two cases preceded by infection (herpes simplex virus encephalitis and tuberculous meningitis) was unremarkable. Treatment included intravenous immunoglobulin/methylprednisolone (11 patients), rituximab (eight patients), plasmapheresis (two patients), and cyclophosphamide (two patients). Six patients recovered completely. Two patients had mild residual neurological deficits, whereas four had severe residual neurological deficits. Two patients had profound autonomic instability, which was the cause of death for one of them. Two patients relapsed at two and six months after the initial recovery. Conclusions We describe the differences and similarities of clinical presentation, test results, and response to treatment of children with anti–N-methyl-D-aspartate receptor encephalitis from India and the United States. Included is a description of one of the youngest patients with anti–N-methyl-D-aspartate receptor encephalitis (five months) and the first patient to be reported in association with tuberculous meningitis.

AB - Objective There is a wide spectrum of clinical manifestations in children with anti–N-methyl-D-aspartate (NMDA) receptor antibody encephalitis from two different health care settings. Methods We describe our experience with 13 patients (median age, 7 years; range, 5 months to 19 years) presenting to tertiary referral centers in India and the United States. Results Initial manifestations were neurological (seizures or movement disorders) in eight patients, and psychiatric (e.g., emotional lability and hallucination) in five patients. Symptoms during the clinical course included seizures in ten patients, movement disorders (dyskinesia and choreiform movements) in 11 patients, and behavioral changes (aggressiveness and insomnia) in ten patients. Concomitant infections (herpes simplex virus 1, tuberculous meningitis, and influenza A) were present in three patients. Analysis of the cerebrospinal fluid in all except two cases preceded by infection (herpes simplex virus encephalitis and tuberculous meningitis) was unremarkable. Treatment included intravenous immunoglobulin/methylprednisolone (11 patients), rituximab (eight patients), plasmapheresis (two patients), and cyclophosphamide (two patients). Six patients recovered completely. Two patients had mild residual neurological deficits, whereas four had severe residual neurological deficits. Two patients had profound autonomic instability, which was the cause of death for one of them. Two patients relapsed at two and six months after the initial recovery. Conclusions We describe the differences and similarities of clinical presentation, test results, and response to treatment of children with anti–N-methyl-D-aspartate receptor encephalitis from India and the United States. Included is a description of one of the youngest patients with anti–N-methyl-D-aspartate receptor encephalitis (five months) and the first patient to be reported in association with tuberculous meningitis.

KW - acute psychosis

KW - autonomic instability

KW - movement disorder

KW - seizures

UR - http://www.scopus.com/inward/record.url?scp=85019090246&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019090246&partnerID=8YFLogxK

U2 - 10.1016/j.pediatrneurol.2017.03.010

DO - 10.1016/j.pediatrneurol.2017.03.010

M3 - Article

C2 - 28506503

AN - SCOPUS:85019090246

VL - 72

SP - 51

EP - 55

JO - Pediatric Neurology

JF - Pediatric Neurology

SN - 0887-8994

ER -